El lunes 23 de octubre de 2017 celebramos una jornada en la Fundación Ramón Areces sobre Microbiota Intestinal: Implicaciones en la Salud y Enfermedad.
Irritable Bowel Syndrome (IBS) and Fecal Microbiota Transplant. A new hope fo...Find Good Health
IBDs including irritable bowel syndrome (ibs) or ulcerative colitis (uc) are a set of diseases developing into an epidemic. The unusual and recent rise in these kind of diseases most notably on developed countries point to a recent and area specific etiology, not a better healthcare and diagnosis.
Recent researchs are pointing to a healthier immune system and intestinal flora in undeveloped countries' population and an imbalance in our gut flora caused by excessive use of antibiotics.
For more information about health and wellbeing visit our site at:
http://findgoodhealth.org/
1) The gut microbiota plays a key role in host development, physiology, and health by modulating the immune system and influencing organ development and metabolism.
2) The gut microbiota is dominated by anaerobic bacteria and contains over 500-1000 bacterial species from a few bacterial phyla. It outnumbers human cells 10:1 and contains many metabolic functions.
3) The gut microbiota influences the properties of the intestinal mucus layer, induces the development of lymphoid structures, and tailors immune development through effects on both the innate and adaptive immune systems.
This document summarizes a presentation on fecal microbiota transplantation (FMT). It begins with an introduction and overview of the history and timeline of FMT. It then discusses the gut microbiota and its indications. The bulk of the document focuses on Clostridium difficile infection, including its pathogenesis and the procedure for FMT. It also covers the advantages and disadvantages of FMT as well as regulatory issues and future research directions.
Patologie digestive, extradigestive e MicrobiotaASMaD
The document discusses the human microbiome and its role in various gastrointestinal diseases. It begins by noting that the microbiome contains over 1000 bacterial species and 1 million genes, far more than the human genome. It then discusses how the microbiome is established during birth and early life, and how it varies over time and geography. The document also explores how dysbiosis, or imbalance of the microbiome, is associated with diseases like IBD, IBS, diverticular disease, obesity and metabolic syndrome. It presents evidence that fecal microbiota transplantation can treat diseases like C. difficile infection and metabolic syndrome. Finally, it discusses potential therapeutic approaches like prebiotics, probiotics, antibiotics and diet to treat dysbiosis
Discovering the 100 Trillion Bacteria Living Within Each of UsLarry Smarr
This document provides a summary of a lecture on the human microbiome given by Dr. Larry Smarr. Some key points:
- The human microbiome refers to the trillions of bacteria that live within the human body. Each person contains 100 trillion bacteria, outnumbering human cells.
- Research into the microbiome is a rapidly growing field that provides insights into health and disease. The microbiome plays a role in processes like drug metabolism and immunity.
- The microbiome is established early in life and influenced by factors like birth method and antibiotic use in the first years. This early development can impact future health.
- Microbiome composition and function can change with health status, diet, medications and other
Human Microbiome is the current project in Research field. The importance of Microorganisms in the human body, the importance and novel roe of the microorganisms on a human body is very effective and helpful. Fecal Transplantation is a unique and helpful technique to cure a dreadful disease naturally by means of microorganisms or introducing the normal flora in to the body again.
Your microbiome may be key factor determining your health and longevitykirti betai
1. Your gut microbiome plays a key role in your health and longevity. A healthy microbiome can help prevent diseases like inflammatory bowel disease and diabetes, while an unhealthy one allows disease to take hold.
2. Certain bacteria in the gut, like Faecalibacterium prausnitzii, appear to have anti-inflammatory properties that can protect against conditions like Crohn's disease. Maintaining a diverse population of beneficial microbes is important for immune function.
3. Widespread antibiotic overuse has fueled deadly infections like Clostridium difficile, which causes life-threatening diarrhea. C. difficile infections are especially prevalent in hospitals and nursing homes.
Irritable Bowel Syndrome (IBS) and Fecal Microbiota Transplant. A new hope fo...Find Good Health
IBDs including irritable bowel syndrome (ibs) or ulcerative colitis (uc) are a set of diseases developing into an epidemic. The unusual and recent rise in these kind of diseases most notably on developed countries point to a recent and area specific etiology, not a better healthcare and diagnosis.
Recent researchs are pointing to a healthier immune system and intestinal flora in undeveloped countries' population and an imbalance in our gut flora caused by excessive use of antibiotics.
For more information about health and wellbeing visit our site at:
http://findgoodhealth.org/
1) The gut microbiota plays a key role in host development, physiology, and health by modulating the immune system and influencing organ development and metabolism.
2) The gut microbiota is dominated by anaerobic bacteria and contains over 500-1000 bacterial species from a few bacterial phyla. It outnumbers human cells 10:1 and contains many metabolic functions.
3) The gut microbiota influences the properties of the intestinal mucus layer, induces the development of lymphoid structures, and tailors immune development through effects on both the innate and adaptive immune systems.
This document summarizes a presentation on fecal microbiota transplantation (FMT). It begins with an introduction and overview of the history and timeline of FMT. It then discusses the gut microbiota and its indications. The bulk of the document focuses on Clostridium difficile infection, including its pathogenesis and the procedure for FMT. It also covers the advantages and disadvantages of FMT as well as regulatory issues and future research directions.
Patologie digestive, extradigestive e MicrobiotaASMaD
The document discusses the human microbiome and its role in various gastrointestinal diseases. It begins by noting that the microbiome contains over 1000 bacterial species and 1 million genes, far more than the human genome. It then discusses how the microbiome is established during birth and early life, and how it varies over time and geography. The document also explores how dysbiosis, or imbalance of the microbiome, is associated with diseases like IBD, IBS, diverticular disease, obesity and metabolic syndrome. It presents evidence that fecal microbiota transplantation can treat diseases like C. difficile infection and metabolic syndrome. Finally, it discusses potential therapeutic approaches like prebiotics, probiotics, antibiotics and diet to treat dysbiosis
Discovering the 100 Trillion Bacteria Living Within Each of UsLarry Smarr
This document provides a summary of a lecture on the human microbiome given by Dr. Larry Smarr. Some key points:
- The human microbiome refers to the trillions of bacteria that live within the human body. Each person contains 100 trillion bacteria, outnumbering human cells.
- Research into the microbiome is a rapidly growing field that provides insights into health and disease. The microbiome plays a role in processes like drug metabolism and immunity.
- The microbiome is established early in life and influenced by factors like birth method and antibiotic use in the first years. This early development can impact future health.
- Microbiome composition and function can change with health status, diet, medications and other
Human Microbiome is the current project in Research field. The importance of Microorganisms in the human body, the importance and novel roe of the microorganisms on a human body is very effective and helpful. Fecal Transplantation is a unique and helpful technique to cure a dreadful disease naturally by means of microorganisms or introducing the normal flora in to the body again.
Your microbiome may be key factor determining your health and longevitykirti betai
1. Your gut microbiome plays a key role in your health and longevity. A healthy microbiome can help prevent diseases like inflammatory bowel disease and diabetes, while an unhealthy one allows disease to take hold.
2. Certain bacteria in the gut, like Faecalibacterium prausnitzii, appear to have anti-inflammatory properties that can protect against conditions like Crohn's disease. Maintaining a diverse population of beneficial microbes is important for immune function.
3. Widespread antibiotic overuse has fueled deadly infections like Clostridium difficile, which causes life-threatening diarrhea. C. difficile infections are especially prevalent in hospitals and nursing homes.
The document summarizes research into the relationship between gut bacteria, bile acids, and cancer risk. Researchers believe that an imbalance in gut bacteria from conditions like diabetes or a Western diet can increase toxic bile acids, raising cancer risk. The researchers aim to determine bacteria's role in gastrointestinal and liver cancers and whether restoring bacterial balance through probiotics can prevent cancer. They will test if a gut bacterium and milk sugars can lower cancer risk by enriching good bacteria, reducing inflammation and toxic bile acids.
This study compared the bacterial communities found in rectal biopsy samples to those found in rectal swab samples from the same patients using 16s ribosomal gene profiling. The results showed significant differences between the bacterial profiles of biopsies and swabs, with swabs exhibiting more diverse communities. Specifically, swab samples had higher levels of certain bacteria like Lactobacillus compared to biopsy samples. This suggests that rectal swabs may not accurately represent the bacteria present in the mucosal tissue.
The gut in critical Illness: A perspective in five acts by Prof. John MarshallSMACC Conference
This document summarizes the history of understanding the relationship between the gut and systemic illness in 5 acts from ancient times to the present. It describes how views have evolved from seeing the gut as a source of illness to recognizing the gut microbiome plays an important role in modulating immunity and disease. Select studies are highlighted showing how dysbiosis of the gut microbiota contributes to sepsis and how probiotics may help reduce infections like ventilator-associated pneumonia.
BRN Symposium 03/06/16 The respiratory microbiome: a new frontier in medicinebrnmomentum
The document discusses the respiratory microbiome and some key uncertainties. It notes that while only about 5% of microorganisms are currently culturable, the microbiome is present. The microbiota of the lower respiratory tract is generally similar to that in the oropharynx, with bacteria like Firmicutes and Bacteroidetes present. However, disease states can disrupt the diversity and relative abundances of bacteria in the respiratory microbiome. Exacerbations of conditions like COPD are also associated with changes in the microbiome. Further research is needed to better understand microbiome interactions and how different bacteria may impact health and disease.
This document discusses the relationships between human nutrition, the gut microbiome, and the immune system. It argues that understanding how diet influences the gut microbiome and immune system could help address global health problems like malnutrition. The marriage of metagenomic methods to study the gut microbiome and gnotobiotic methods using germ-free animals could provide insights into these relationships and help test hypotheses. Dietary patterns are changing worldwide due to various social and economic factors, and understanding how these changes impact the gut microbiome may provide clues about nutritional status and immune function.
Treating Clostridium Difficile Infection With Faecal Microbiota TransplantationEdith Ngobi
Faecal microbiota transplantation (FMT) involves transplanting stool from a healthy donor into a patient with recurrent Clostridium difficile infection (CDI) in order to restore the normal gut flora. FMT has a cure rate over 90% for recurrent CDI and works by reintroducing bacteria that can suppress C. difficile growth and prevent toxin production. While it has significant advantages over antibiotic treatment, standardization of procedures and screening donors is needed before FMT can become a first-line treatment option.
Microbiota, leaky gut syndrome and gut-related diseasesMaurizio Salamone
1. The gut microbiota plays an important role in metabolic, barrier, and immune functions that influence human health. An imbalance in gut bacteria (dysbiosis) is involved in many gastrointestinal disorders.
2. Maintaining balance between gut bacteria species and the host is crucial, as dysbiosis can lead to increased intestinal permeability ("leaky gut") and low-grade inflammation, contributing to conditions like IBS, IBD, obesity, and diabetes.
3. Modulating the gut microbiota through probiotics, prebiotics, dietary changes, and supplements can help restore balance and proper communication between bacteria and host, potentially improving gastrointestinal symptoms and health.
Impact of gut microbes on gastrointestinal diseaseSandra Unorji
Gut microbes have been identified play a role in both health and disease. Surprisingly, we are outnumbered by them which raises questions that has led to several research with interesting results.
Interactions of the Immune System with the Gut Microbiome in Inflammatory Bo...Larry Smarr
Larry Smarr presented on his research quantifying interactions between his immune system, gut microbiome, and genetics in relation to his diagnosis of Crohn's disease. Over many years, he collected over 150 biological variables from blood and stool samples, and obtained genomic and metagenomic sequencing. Analysis revealed periods of chronic inflammation correlated with shifts in bacterial abundance and invasive strains. Treatment with antibiotics and immunosuppressants reduced inflammation and allowed rare bacteria to decrease while more beneficial firms increased. The research aims to better understand coupled human-microbiome dynamics and how genetics may predispose individuals to conditions like inflammatory bowel disease.
Food allergy has been long recognized and well documented. Other adverse reactions to foods first referred to as “toxic idiopathies” by John Freeman, co inventor of immunotherapy, at the early part of the 1900s can be mediated by and have their impact on the nervous and endocrine systems. It can also be mediated by pharmacologic mechanisms and can also affect any part of the body. There’s a great clinical need to accurately identify triggers of adverse reactivity as they have now been linked with even the most serious of modern maladies and diseases. In fact, inflammation is the hallmark of metabolic syndrome. Given the multitude of pathogenic mechanisms underlying adverse reactions to foods and other environmental exposures it is necessary that a utilizable and cost effective technology be understood so that its application be utilized under the appropriate circumstances.
KEY LEARNING POINTS
• The natural ability of certain foods to initiate an inflammatory response and induce metabolic disruptions and counterbalancing mechanisms to prevent that
• How foods can trigger “danger signals” for the immune system
Pharmacologic vs. immunologic reactions to foods
• Is there a common final pathway of all these mechanisms that can reliably indicate triggers of clinical pathology?
• Cellular testing vs. serologic testing: The advantages of cellular testing
This document summarizes current knowledge about microbial biofilms in the gastrointestinal (GI) tract and their association with health and disease. It discusses how the GI tract provides many environments suitable for biofilm formation. Several diseases are implicated as involving GI biofilms, including Barrett's esophagus and Helicobacter pylori infections. Studies have found distinct microbial communities and biofilms in patients with Barrett's esophagus compared to controls. H. pylori is able to form biofilms in the stomach that may help it persist and contribute to diseases like peptic ulcers. Overall, the review examines the composition and potential roles of microbial biofilms throughout the GI tract.
The document discusses factors that influence the development of the infant microbiome and its potential link to obesity risk later in life. It states that the microbiome develops both before and after birth, and is shaped by factors like birth mode, initial feeding method, antibiotic use, and diet. Diet plays the most significant role after infancy, with high fiber diets cultivating more diverse microbiomes. The composition of the infant microbiome may impact obesity risk through the microbiome's role in energy regulation and inflammation. Alterations in the microbiome could increase obesity risk through mechanisms like increased energy harvest from food, raised inflammatory responses, and changes in lipid metabolism.
This document discusses antibiotic-associated diarrhea (AAD) and Clostridium difficile infection (CDI). It provides information on the mechanisms by which antibiotics can cause diarrhea, such as altering intestinal flora and bacterial overgrowth. It also discusses various pathogens that can cause AAD, including C. difficile, C. perfringens, K. oxytoca, and S. aureus. The document outlines the clinical presentation, diagnosis, risk factors and complications of CDI. It describes treatments for CDI including metronidazole, vancomycin and newer approaches like fecal transplants.
VHIR Seminar led by Joel Doré. Research Director. Institut National de la Recherche Agronomique (INRA). Jouy-en-Josas, France.
Abstract: The human intestinal tract harbours a complex microbial ecosystem which plays a key role in nutrition and health. Interactions between food constituents, microbes and the host organism derive from a long co-evolution that resulted in a mutualistic association.
Current investigations into the human faecal metagenome are delivering an extensive gene repertoire representative of functional potentials of the human intestinal microbiota. The most redundant genomic traits of the human intestinal microbiota are identified and thereby its functional balance. These observation point towards the existence of enterotypes, i.e. microbiota sharing specific traits but yet independent of geographic origin, age, sex etc.. It also shows a unique segregation of the human population into individuals with low versus high gene-counts. In the end, it not only gives an unprecedented view of the intestinal microbiota, but it also significantly expands our ability to look for specificities of the microbiota associated with human diseases and to ultimately validate microbial signatures of prognostic and diagnostic value in immune mediated diseases.
Metagenomics of the human intestinal tract was applied to specifically compare obese versus lean individuals as well as to explore the dynamic changes associated with a severe calory-restricted diet. Microbiota structure differs with body-mass index and a limited set of marker species may be used as diagnostic model with a >85% predictive value. Among obese subjects; the overall phenotypic characteristics are worse in individuals with low gene counts microbiota, including a worse evolution of morphometric parameters over a period of 10 years, a low grade inflammatory context also associated with insulin-resistance, and the worst response to dietary constraints in terms of weight loss or improvement of biological and inflammatory characteristics. Low gene count microbiota is also associated with less favourable conditions in inflammatory bowel disease, such as higher relapse rate in ulcerative colitis patients.
Finally, microbiota transplantation has seen a regain of interest with applications expanding from Clostridium difficile infections to immune mediated and metabolic diseases.
The human intestinal microbiota should hence be regarded as a true organ, amenable to rationally designed modulation for human health.
Tracking Large Variations in My Immune Biomarkers and My Gut Microbiome: Infl...Larry Smarr
This document provides a 3-sentence summary of a presentation by Dr. Larry Smarr on tracking changes in his immune biomarkers and gut microbiome in relation to inflammation, Crohn's disease, and colon cancer:
Over the past decade, Dr. Smarr has quantified over a billion data points on his body through measures like blood tests, MRI/CT scans, and analysis of his gut microbiome, discovering through this data that he has episodic chronic inflammation and Crohn's disease affecting his colon. By comparing his biomarkers and symptoms over time and visualizing his microbiome ecology, Dr. Smarr has gained insights into the dynamics and invasiveness of species in his gut microbiome as it relates to his autoimmune
Microbiota y la respuesta immune - Dra Romina GoldszmidWebee by Formar
This document discusses the role of the human microbiome and its interaction with the immune system. It notes that humans are composed of both human and microbial cells that co-evolve and interact. The microbiome plays a key role in immune system development and homeostasis. The microbes inhabit all barrier surfaces of the body and outnumber human cells. They have a significant impact on local and systemic immunity and inflammation, as well as diseases like cancer, metabolic disorders, and neurological/behavioral functions. The microbiome composition is shaped by various environmental factors and can be modulated to impact health outcomes.
This document discusses gut microbiota and its relationship to diabetes. It begins with an overview of gut microbiota functions and compositions. It then describes how gut microbiota can be related to both type 1 and type 2 diabetes pathogenesis through various mechanisms like inflammatory responses and metabolic endotoxemia. The document discusses findings from metagenomic studies that show differences in gut microbiota of diabetes patients compared to healthy individuals. It also presents results from an Indo-Danish collaborative study on gut microbiome signatures associated with pre-diabetes and type 2 diabetes in Indian and Danish populations.
1. The document discusses gut microbiota and its relationship to health. It provides background on methods used to study the microbiome, such as next generation sequencing and fecal transplantation.
2. Intrinsic and extrinsic factors that influence microbiome composition are examined, including genetics, diet, medication, and disease states. Many diseases are associated with distinct microbiome profiles.
3. Studies of population cohorts explore the effects of various factors on the microbiome and identify biomarkers. Comparisons of healthy, IBS, and IBD groups show differences in taxonomic profiles and metabolic pathways between conditions.
The document summarizes research into the relationship between gut bacteria, bile acids, and cancer risk. Researchers believe that an imbalance in gut bacteria from conditions like diabetes or a Western diet can increase toxic bile acids, raising cancer risk. The researchers aim to determine bacteria's role in gastrointestinal and liver cancers and whether restoring bacterial balance through probiotics can prevent cancer. They will test if a gut bacterium and milk sugars can lower cancer risk by enriching good bacteria, reducing inflammation and toxic bile acids.
This study compared the bacterial communities found in rectal biopsy samples to those found in rectal swab samples from the same patients using 16s ribosomal gene profiling. The results showed significant differences between the bacterial profiles of biopsies and swabs, with swabs exhibiting more diverse communities. Specifically, swab samples had higher levels of certain bacteria like Lactobacillus compared to biopsy samples. This suggests that rectal swabs may not accurately represent the bacteria present in the mucosal tissue.
The gut in critical Illness: A perspective in five acts by Prof. John MarshallSMACC Conference
This document summarizes the history of understanding the relationship between the gut and systemic illness in 5 acts from ancient times to the present. It describes how views have evolved from seeing the gut as a source of illness to recognizing the gut microbiome plays an important role in modulating immunity and disease. Select studies are highlighted showing how dysbiosis of the gut microbiota contributes to sepsis and how probiotics may help reduce infections like ventilator-associated pneumonia.
BRN Symposium 03/06/16 The respiratory microbiome: a new frontier in medicinebrnmomentum
The document discusses the respiratory microbiome and some key uncertainties. It notes that while only about 5% of microorganisms are currently culturable, the microbiome is present. The microbiota of the lower respiratory tract is generally similar to that in the oropharynx, with bacteria like Firmicutes and Bacteroidetes present. However, disease states can disrupt the diversity and relative abundances of bacteria in the respiratory microbiome. Exacerbations of conditions like COPD are also associated with changes in the microbiome. Further research is needed to better understand microbiome interactions and how different bacteria may impact health and disease.
This document discusses the relationships between human nutrition, the gut microbiome, and the immune system. It argues that understanding how diet influences the gut microbiome and immune system could help address global health problems like malnutrition. The marriage of metagenomic methods to study the gut microbiome and gnotobiotic methods using germ-free animals could provide insights into these relationships and help test hypotheses. Dietary patterns are changing worldwide due to various social and economic factors, and understanding how these changes impact the gut microbiome may provide clues about nutritional status and immune function.
Treating Clostridium Difficile Infection With Faecal Microbiota TransplantationEdith Ngobi
Faecal microbiota transplantation (FMT) involves transplanting stool from a healthy donor into a patient with recurrent Clostridium difficile infection (CDI) in order to restore the normal gut flora. FMT has a cure rate over 90% for recurrent CDI and works by reintroducing bacteria that can suppress C. difficile growth and prevent toxin production. While it has significant advantages over antibiotic treatment, standardization of procedures and screening donors is needed before FMT can become a first-line treatment option.
Microbiota, leaky gut syndrome and gut-related diseasesMaurizio Salamone
1. The gut microbiota plays an important role in metabolic, barrier, and immune functions that influence human health. An imbalance in gut bacteria (dysbiosis) is involved in many gastrointestinal disorders.
2. Maintaining balance between gut bacteria species and the host is crucial, as dysbiosis can lead to increased intestinal permeability ("leaky gut") and low-grade inflammation, contributing to conditions like IBS, IBD, obesity, and diabetes.
3. Modulating the gut microbiota through probiotics, prebiotics, dietary changes, and supplements can help restore balance and proper communication between bacteria and host, potentially improving gastrointestinal symptoms and health.
Impact of gut microbes on gastrointestinal diseaseSandra Unorji
Gut microbes have been identified play a role in both health and disease. Surprisingly, we are outnumbered by them which raises questions that has led to several research with interesting results.
Interactions of the Immune System with the Gut Microbiome in Inflammatory Bo...Larry Smarr
Larry Smarr presented on his research quantifying interactions between his immune system, gut microbiome, and genetics in relation to his diagnosis of Crohn's disease. Over many years, he collected over 150 biological variables from blood and stool samples, and obtained genomic and metagenomic sequencing. Analysis revealed periods of chronic inflammation correlated with shifts in bacterial abundance and invasive strains. Treatment with antibiotics and immunosuppressants reduced inflammation and allowed rare bacteria to decrease while more beneficial firms increased. The research aims to better understand coupled human-microbiome dynamics and how genetics may predispose individuals to conditions like inflammatory bowel disease.
Food allergy has been long recognized and well documented. Other adverse reactions to foods first referred to as “toxic idiopathies” by John Freeman, co inventor of immunotherapy, at the early part of the 1900s can be mediated by and have their impact on the nervous and endocrine systems. It can also be mediated by pharmacologic mechanisms and can also affect any part of the body. There’s a great clinical need to accurately identify triggers of adverse reactivity as they have now been linked with even the most serious of modern maladies and diseases. In fact, inflammation is the hallmark of metabolic syndrome. Given the multitude of pathogenic mechanisms underlying adverse reactions to foods and other environmental exposures it is necessary that a utilizable and cost effective technology be understood so that its application be utilized under the appropriate circumstances.
KEY LEARNING POINTS
• The natural ability of certain foods to initiate an inflammatory response and induce metabolic disruptions and counterbalancing mechanisms to prevent that
• How foods can trigger “danger signals” for the immune system
Pharmacologic vs. immunologic reactions to foods
• Is there a common final pathway of all these mechanisms that can reliably indicate triggers of clinical pathology?
• Cellular testing vs. serologic testing: The advantages of cellular testing
This document summarizes current knowledge about microbial biofilms in the gastrointestinal (GI) tract and their association with health and disease. It discusses how the GI tract provides many environments suitable for biofilm formation. Several diseases are implicated as involving GI biofilms, including Barrett's esophagus and Helicobacter pylori infections. Studies have found distinct microbial communities and biofilms in patients with Barrett's esophagus compared to controls. H. pylori is able to form biofilms in the stomach that may help it persist and contribute to diseases like peptic ulcers. Overall, the review examines the composition and potential roles of microbial biofilms throughout the GI tract.
The document discusses factors that influence the development of the infant microbiome and its potential link to obesity risk later in life. It states that the microbiome develops both before and after birth, and is shaped by factors like birth mode, initial feeding method, antibiotic use, and diet. Diet plays the most significant role after infancy, with high fiber diets cultivating more diverse microbiomes. The composition of the infant microbiome may impact obesity risk through the microbiome's role in energy regulation and inflammation. Alterations in the microbiome could increase obesity risk through mechanisms like increased energy harvest from food, raised inflammatory responses, and changes in lipid metabolism.
This document discusses antibiotic-associated diarrhea (AAD) and Clostridium difficile infection (CDI). It provides information on the mechanisms by which antibiotics can cause diarrhea, such as altering intestinal flora and bacterial overgrowth. It also discusses various pathogens that can cause AAD, including C. difficile, C. perfringens, K. oxytoca, and S. aureus. The document outlines the clinical presentation, diagnosis, risk factors and complications of CDI. It describes treatments for CDI including metronidazole, vancomycin and newer approaches like fecal transplants.
VHIR Seminar led by Joel Doré. Research Director. Institut National de la Recherche Agronomique (INRA). Jouy-en-Josas, France.
Abstract: The human intestinal tract harbours a complex microbial ecosystem which plays a key role in nutrition and health. Interactions between food constituents, microbes and the host organism derive from a long co-evolution that resulted in a mutualistic association.
Current investigations into the human faecal metagenome are delivering an extensive gene repertoire representative of functional potentials of the human intestinal microbiota. The most redundant genomic traits of the human intestinal microbiota are identified and thereby its functional balance. These observation point towards the existence of enterotypes, i.e. microbiota sharing specific traits but yet independent of geographic origin, age, sex etc.. It also shows a unique segregation of the human population into individuals with low versus high gene-counts. In the end, it not only gives an unprecedented view of the intestinal microbiota, but it also significantly expands our ability to look for specificities of the microbiota associated with human diseases and to ultimately validate microbial signatures of prognostic and diagnostic value in immune mediated diseases.
Metagenomics of the human intestinal tract was applied to specifically compare obese versus lean individuals as well as to explore the dynamic changes associated with a severe calory-restricted diet. Microbiota structure differs with body-mass index and a limited set of marker species may be used as diagnostic model with a >85% predictive value. Among obese subjects; the overall phenotypic characteristics are worse in individuals with low gene counts microbiota, including a worse evolution of morphometric parameters over a period of 10 years, a low grade inflammatory context also associated with insulin-resistance, and the worst response to dietary constraints in terms of weight loss or improvement of biological and inflammatory characteristics. Low gene count microbiota is also associated with less favourable conditions in inflammatory bowel disease, such as higher relapse rate in ulcerative colitis patients.
Finally, microbiota transplantation has seen a regain of interest with applications expanding from Clostridium difficile infections to immune mediated and metabolic diseases.
The human intestinal microbiota should hence be regarded as a true organ, amenable to rationally designed modulation for human health.
Tracking Large Variations in My Immune Biomarkers and My Gut Microbiome: Infl...Larry Smarr
This document provides a 3-sentence summary of a presentation by Dr. Larry Smarr on tracking changes in his immune biomarkers and gut microbiome in relation to inflammation, Crohn's disease, and colon cancer:
Over the past decade, Dr. Smarr has quantified over a billion data points on his body through measures like blood tests, MRI/CT scans, and analysis of his gut microbiome, discovering through this data that he has episodic chronic inflammation and Crohn's disease affecting his colon. By comparing his biomarkers and symptoms over time and visualizing his microbiome ecology, Dr. Smarr has gained insights into the dynamics and invasiveness of species in his gut microbiome as it relates to his autoimmune
Microbiota y la respuesta immune - Dra Romina GoldszmidWebee by Formar
This document discusses the role of the human microbiome and its interaction with the immune system. It notes that humans are composed of both human and microbial cells that co-evolve and interact. The microbiome plays a key role in immune system development and homeostasis. The microbes inhabit all barrier surfaces of the body and outnumber human cells. They have a significant impact on local and systemic immunity and inflammation, as well as diseases like cancer, metabolic disorders, and neurological/behavioral functions. The microbiome composition is shaped by various environmental factors and can be modulated to impact health outcomes.
This document discusses gut microbiota and its relationship to diabetes. It begins with an overview of gut microbiota functions and compositions. It then describes how gut microbiota can be related to both type 1 and type 2 diabetes pathogenesis through various mechanisms like inflammatory responses and metabolic endotoxemia. The document discusses findings from metagenomic studies that show differences in gut microbiota of diabetes patients compared to healthy individuals. It also presents results from an Indo-Danish collaborative study on gut microbiome signatures associated with pre-diabetes and type 2 diabetes in Indian and Danish populations.
1. The document discusses gut microbiota and its relationship to health. It provides background on methods used to study the microbiome, such as next generation sequencing and fecal transplantation.
2. Intrinsic and extrinsic factors that influence microbiome composition are examined, including genetics, diet, medication, and disease states. Many diseases are associated with distinct microbiome profiles.
3. Studies of population cohorts explore the effects of various factors on the microbiome and identify biomarkers. Comparisons of healthy, IBS, and IBD groups show differences in taxonomic profiles and metabolic pathways between conditions.
The document summarizes an annual probiotic symposium held in Chennai, India in December 2016. It includes an agenda with presentations on the role of probiotics in gastrointestinal diseases, the equilibrium of the gut flora, the history and definitions of probiotics and prebiotics, how probiotics function and their anti-inflammatory and immunomodulatory effects. It also discusses the clinical applications of probiotics in gastrointestinal disorders like diarrhea, IBD, IBS, obesity, and intestinal pain. Studies presented show probiotics can reduce NAFLD in obese children and infections in critical illness.
The document summarizes an annual probiotic symposium held in Chennai, India in December 2016. It includes the following:
- An agenda for the symposium that covers definitions of probiotics, prebiotics, and synbiotics; the history of probiotics; the role of probiotics in gastrointestinal diseases; their functions and mechanisms of action; clinical applications in gastroenterology; dosage and safety issues; and conclusions.
- Presentations on the topics of probiotics in gastrointestinal diseases, their equilibrium in nature and the human body, and the gut flora.
- Evidence that certain probiotic strains like Lactobacillus and Bifidobacterium can reduce disease activity and symptoms
The document discusses the relationship between the gut and joints in rheumatoid arthritis (RA). It suggests that gut-joint interactions are an important part of RA pathogenesis, as is becoming clearer. Dysbiosis of the gut microbiome occurs before clinical onset of RA and likely influences disease development. This dysbiosis could open up new therapeutic opportunities, such as restoring microbial balance and preventing trafficking of immune cells from the gut to the joints. Considering the role of the gut-joint axis in RA pathogenesis offers possibilities for new early-stage treatments to reduce RA symptoms.
Microbiome & Infection Control - NJ FawcettNicola Fawcett
This document discusses the human microbiome and its role in infection prevention and control. It covers how antibiotics can disrupt the microbiome and increase risks of infection by multidrug-resistant organisms. Probiotics, prebiotics, synbiotics, and fecal microbiota transplant are presented as potential strategies for microbiome restoration and pathogen decolonization. The intact human microbiome is described as an important host defense against pathogen colonization and infection.
This document discusses the role of probiotics in adult gastroenterology. It provides a brief history of probiotics dating back to Elie Metchnikof in 1908. Probiotics are defined as live microorganisms that provide health benefits when consumed. The gut microbiota plays an important role in health, and probiotics may help treat or prevent conditions caused by microbial imbalances like infectious diarrhea, irritable bowel syndrome, inflammatory bowel disease, obesity, and liver diseases. Probiotics have demonstrated benefits, but their effects tend to be strain-specific and more research is still needed, especially for conditions like Crohn's disease. Safety concerns also exist for certain at-risk populations.
Human intestinal microbiome in health and diseasesarnab ghosh
This document summarizes research on the human intestinal microbiome. It discusses how culture-independent techniques have revealed the enormous diversity of microbes in the human gut. The gut microbiota plays important roles in immunity, metabolism, and other bodily functions, and imbalances are associated with various diseases. The composition of the gut microbiota changes over a person's lifetime from birth through adulthood and old age due to factors like mode of birth, diet, antibiotic use, and age-related immune changes. Understanding these dynamics may lead to new disease treatments targeting the gut microbiome.
Probiotics may play a role in inflammatory bowel disease (IBD). In ulcerative colitis, probiotics like VSL#3 have been shown to induce remission in mild-to-moderate disease, maintain remission, and treat pouchitis. Certain probiotic strains are more effective than others. In Crohn's disease, VSL#3 and S. boulardii have demonstrated benefits like maintaining remission and improving intestinal permeability when used as an adjunct to standard therapies. Well-designed studies provide evidence for the therapeutic potential of specific probiotic strains in both ulcerative colitis and Crohn's disease.
Human Gut Mycobiota is still a mistery for us. Most of the reasearch on this topichas been conducted in the last 5 years. We are starting to comprehend the interactions with our gastrointestinal system and the virus and bacterial communities. 13% of gut microbiota in weight, about 150 species; most of them can shift from commensalism to virulent parassitosis according to our immune competence. Gut fungal overgrowth is actually underestimated in dignaosis and treatment. Many FGIDS and SIBO are frequently mixed bacteral and fungal dysbiosis
Safety assessment of probiotics for human useDiwas Pradhan
The document summarizes safety assessment procedures for probiotic bacteria intended for human use. It defines probiotics and lists common strains used. Safety assessment includes taxonomic identification, assessing absence of pathogenicity and undesirable metabolic activities, determining antibiotic resistance and potential for horizontal gene transfer, and validation in animal models. Human studies are also important to establish tolerability and identify any adverse effects. Overall, the document outlines guidelines and criteria for evaluating probiotic safety prior to human use based on established scientific principles and evidence from the literature.
This document provides an overview of Helicobacter pylori, including its historical discovery in 1982 by Marshall and Warren which revolutionized ulcer treatment. It describes H. pylori's morphology as a spiral-shaped, flagellated, gram-negative bacterium that lives in the stomach mucus layer. The document discusses H. pylori's worldwide prevalence, routes of transmission, virulence factors, mechanisms of infection, associated diseases like ulcers and stomach cancer, and laboratory tests for diagnosis. In conclusion, H. pylori infection typically causes long-term gastritis in most cases, while clinical complications represent an imbalance in gastric homeostasis.
This document provides a literature review on inflammatory bowel disease (IBD). It summarizes definitions of IBD from the 2015 World Gastroenterology Organization guidelines and a 2016 Nature Reviews article. It then reviews the epidemiology of IBD globally and in Mexico. The pathophysiology section discusses predisposing factors like environment, microbiota, genetics, and the immune response. Specific sections cover Crohn's disease, ulcerative colitis, and other pathogenic pathways. The document cites over 15 references on epidemiology, clinical aspects, treatments, and the immunopathogenesis of IBD.
Microbiome: The genes and genomes of the microbiota, as well as the products of the microbiota and the host environment” [the collective genomes of the micro-organisms in a particular environment. Although the composition of the gut microbiota varies between individuals, the community in each individual is relatively stable over time.
The document discusses the human gut microbiota and its therapeutic applications. It provides details on the composition and functions of the gut microbiota, factors that influence it, methods for assessing its functions, and associated diseases. It also discusses probiotics, prebiotics, postbiotics, fecal microbiota transplantation, and the development of microbiome-based therapeutics to modulate the gut microbiota for therapeutic purposes.
colon drug delivery- advantage and disadvantage of colon delivery, anatomy of colon in healthy and diseased state , different approaches (conventional and new) for colon delivery, in vitro and in vivo evaluation
The document is a poem describing the various microhabitats within the human body that are suitable for commensal microbes to colonize, including pores, arm pits, and scalp. It welcomes microbes to build colonies and supplies them warmth, moisture, and nutrients, on the condition they do not cause issues like acne or athlete's foot. The poem acknowledges microbes as guests in the body on this new year's day.
BRN Symposium 03/06/16 Lesson from the human gut microbiomebrnmomentum
This document summarizes information about the human gut microbiota from several studies and sources. It discusses how the gut microbiota is established at birth and colonized depending on delivery method. Methods for studying the microbiome including sequencing and analysis are presented. The composition and functions of the gut microbiota are described, and its interaction with the immune system. Dysbiosis and lower diversity are associated with several diseases like obesity, diabetes, and cirrhosis. Intervention studies show diet can impact the microbiota in obese individuals. Fecal microbiota transplantation is discussed as a treatment for C. difficile infection.
Similar to Francisco Guarner Hospital Universitari Vall d'Hebron. (20)
Jordi Torren - Coordinador del proyecto ESVAC. Agencia Europea de Medicamento...Fundación Ramón Areces
El martes 5 de junio del 2018 organizamos una Jornada en la Fundación Ramón Areces, en la cual se habló sobre el consumo de antibióticos y transmisión de resistencia entre humanos y animales.
Dominique L. Monnet Director del programa ARHAI (Antimicrobial Resistance an...Fundación Ramón Areces
El martes 5 de junio del 2018 organizamos una Jornada en la Fundación Ramón Areces, en la cual se habló sobre el consumo de antibióticos y transmisión de resistencia entre humanos y animales.
El jueves 24 de mayo del 2018 organizamos una Conferencia con Antonio Cabrales en la Fundación Ramón Areces. Una conferencia en la cual el tema fue: Estilo negociador y confianza, ¿hay diferencias entre hombres y mujeres?
Teresa Puig - Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Espa...Fundación Ramón Areces
El lunes y martes 21 y 22 de mayo del 2018 realizamos un Simposio Internacional en la Fundación Ramón Areces, tratando el tema de la superconductividad y presión: una relación fructífera en el camino hacia la superconductividad a temperatura ambiente.
Elena Bascones - Instituto de Ciencia de Materiales de Madrid (ICMM-CSIC), Es...Fundación Ramón Areces
El lunes y martes 21 y 22 de mayo del 2018 realizamos un Simposio Internacional en la Fundación Ramón Areces, tratando el tema de la superconductividad y presión: una relación fructífera en el camino hacia la superconductividad a temperatura ambiente.
El jueves 17 de mayo del 2018 se organizó una Mesa Redonda en la Fundación Ramón Areces, en la cual se habló sobre las subidas de tipos en la era Trump y la nueva globalización.
El jueves 17 de mayo del 2018 se organizó una Mesa Redonda en la Fundación Ramón Areces, en la cual se habló sobre las subidas de tipos en la era Trump y la nueva globalización.
El miércoles 16 de mayo del 2018 celebramos una Jornada en la Fundación Ramón Areces, en la cual se habló sobre las nuevas fronteras de investigación sobre la distribución comercial y el comportamiento del consumidor.
El miércoles 16 de mayo del 2018 celebramos una Jornada en la Fundación Ramón Areces, en la cual se habló sobre las nuevas fronteras de investigación sobre la distribución comercial y el comportamiento del consumidor.
Juan Carlos López-Gutiérrez - Unidad de Anomalías Vasculares, Hospital Unive...Fundación Ramón Areces
El jueves y viernes 10 y 11 de mayo del 2018 realizamos en la Fundación Ramón Areces un Simposio Internacional, en el cual se trató el tema del mosaicismo somático en malformaciones vasculares.
Víctor Martínez-Glez. - Instituto de Genética Médica y Molecular (INGEMM). I...Fundación Ramón Areces
El jueves y viernes 10 y 11 de mayo del 2018 realizamos en la Fundación Ramón Areces un Simposio Internacional, en el cual se trató el tema del mosaicismo somático en malformaciones vasculares.
Rudolf Happle - Dermatología, University of Freiburg Medical Center, Freiburg...Fundación Ramón Areces
El jueves y viernes 10 y 11 de mayo del 2018 realizamos en la Fundación Ramón Areces un Simposio Internacional, en el cual se trató el tema del mosaicismo somático en malformaciones vasculares.
Rafael Doménech - Responsable de Análisis Macroeconómico, BBVA Research. Fundación Ramón Areces
El martes 8 de mayo de 2018 realizamos una conferencia en la Fundación Ramón Areces, en la cual se habló sobre el futuro de las pensiones: una visión global.
El martes 8 de mayo de 2018 realizamos una conferencia en la Fundación Ramón Areces, en la cual se habló sobre el futuro de las pensiones: una visión global.
El martes 8 de mayo de 2018 realizamos una conferencia en la Fundación Ramón Areces, en la cual se habló sobre el futuro de las pensiones: una visión global.
Nicholas Barr - Profesor de Economía Pública, London School of Economics. Fundación Ramón Areces
El martes 8 de mayo de 2018 realizamos una conferencia en la Fundación Ramón Areces, en la cual se habló sobre el futuro de las pensiones: una visión global.
El viernes 27 de abril del 2018 se celebró en la Fundación Ramón Areces una Jornada sobre física , en la cual se trataron diversos temas como: Los materiales mecanocalóricos, magnetísmo, biofísica, la energía oscura y instrumentación astronómica.
El viernes 20 de abril organizamos una Jornada sobre la ciencia en el corazón de Europa, en colaboración con Científicos Españoles en Bélgica (CEBE) y realizada en la Fundación Ramón Areces.
Marta Olivares - Investigadora Postdoctoral en Université catholique de Louva...Fundación Ramón Areces
El viernes 20 de abril organizamos una Jornada sobre la ciencia en el corazón de Europa, en colaboración con Científicos Españoles en Bélgica (CEBE) y realizada en la Fundación Ramón Areces.
El viernes 20 de abril organizamos una Jornada sobre la ciencia en el corazón de Europa, en colaboración con Científicos Españoles en Bélgica (CEBE) y realizada en la Fundación Ramón Areces.
Evidence of Jet Activity from the Secondary Black Hole in the OJ 287 Binary S...Sérgio Sacani
Wereport the study of a huge optical intraday flare on 2021 November 12 at 2 a.m. UT in the blazar OJ287. In the binary black hole model, it is associated with an impact of the secondary black hole on the accretion disk of the primary. Our multifrequency observing campaign was set up to search for such a signature of the impact based on a prediction made 8 yr earlier. The first I-band results of the flare have already been reported by Kishore et al. (2024). Here we combine these data with our monitoring in the R-band. There is a big change in the R–I spectral index by 1.0 ±0.1 between the normal background and the flare, suggesting a new component of radiation. The polarization variation during the rise of the flare suggests the same. The limits on the source size place it most reasonably in the jet of the secondary BH. We then ask why we have not seen this phenomenon before. We show that OJ287 was never before observed with sufficient sensitivity on the night when the flare should have happened according to the binary model. We also study the probability that this flare is just an oversized example of intraday variability using the Krakow data set of intense monitoring between 2015 and 2023. We find that the occurrence of a flare of this size and rapidity is unlikely. In machine-readable Tables 1 and 2, we give the full orbit-linked historical light curve of OJ287 as well as the dense monitoring sample of Krakow.
(June 12, 2024) Webinar: Development of PET theranostics targeting the molecu...Scintica Instrumentation
Targeting Hsp90 and its pathogen Orthologs with Tethered Inhibitors as a Diagnostic and Therapeutic Strategy for cancer and infectious diseases with Dr. Timothy Haystead.
BIRDS DIVERSITY OF SOOTEA BISWANATH ASSAM.ppt.pptxgoluk9330
Ahota Beel, nestled in Sootea Biswanath Assam , is celebrated for its extraordinary diversity of bird species. This wetland sanctuary supports a myriad of avian residents and migrants alike. Visitors can admire the elegant flights of migratory species such as the Northern Pintail and Eurasian Wigeon, alongside resident birds including the Asian Openbill and Pheasant-tailed Jacana. With its tranquil scenery and varied habitats, Ahota Beel offers a perfect haven for birdwatchers to appreciate and study the vibrant birdlife that thrives in this natural refuge.
TOPIC OF DISCUSSION: CENTRIFUGATION SLIDESHARE.pptxshubhijain836
Centrifugation is a powerful technique used in laboratories to separate components of a heterogeneous mixture based on their density. This process utilizes centrifugal force to rapidly spin samples, causing denser particles to migrate outward more quickly than lighter ones. As a result, distinct layers form within the sample tube, allowing for easy isolation and purification of target substances.
PPT on Sustainable Land Management presented at the three-day 'Training and Validation Workshop on Modules of Climate Smart Agriculture (CSA) Technologies in South Asia' workshop on April 22, 2024.
JAMES WEBB STUDY THE MASSIVE BLACK HOLE SEEDSSérgio Sacani
The pathway(s) to seeding the massive black holes (MBHs) that exist at the heart of galaxies in the present and distant Universe remains an unsolved problem. Here we categorise, describe and quantitatively discuss the formation pathways of both light and heavy seeds. We emphasise that the most recent computational models suggest that rather than a bimodal-like mass spectrum between light and heavy seeds with light at one end and heavy at the other that instead a continuum exists. Light seeds being more ubiquitous and the heavier seeds becoming less and less abundant due the rarer environmental conditions required for their formation. We therefore examine the different mechanisms that give rise to different seed mass spectrums. We show how and why the mechanisms that produce the heaviest seeds are also among the rarest events in the Universe and are hence extremely unlikely to be the seeds for the vast majority of the MBH population. We quantify, within the limits of the current large uncertainties in the seeding processes, the expected number densities of the seed mass spectrum. We argue that light seeds must be at least 103 to 105 times more numerous than heavy seeds to explain the MBH population as a whole. Based on our current understanding of the seed population this makes heavy seeds (Mseed > 103 M⊙) a significantly more likely pathway given that heavy seeds have an abundance pattern than is close to and likely in excess of 10−4 compared to light seeds. Finally, we examine the current state-of-the-art in numerical calculations and recent observations and plot a path forward for near-future advances in both domains.
PPT on Direct Seeded Rice presented at the three-day 'Training and Validation Workshop on Modules of Climate Smart Agriculture (CSA) Technologies in South Asia' workshop on April 22, 2024.
The cost of acquiring information by natural selectionCarl Bergstrom
This is a short talk that I gave at the Banff International Research Station workshop on Modeling and Theory in Population Biology. The idea is to try to understand how the burden of natural selection relates to the amount of information that selection puts into the genome.
It's based on the first part of this research paper:
The cost of information acquisition by natural selection
Ryan Seamus McGee, Olivia Kosterlitz, Artem Kaznatcheev, Benjamin Kerr, Carl T. Bergstrom
bioRxiv 2022.07.02.498577; doi: https://doi.org/10.1101/2022.07.02.498577
SDSS1335+0728: The awakening of a ∼ 106M⊙ black hole⋆Sérgio Sacani
Context. The early-type galaxy SDSS J133519.91+072807.4 (hereafter SDSS1335+0728), which had exhibited no prior optical variations during the preceding two decades, began showing significant nuclear variability in the Zwicky Transient Facility (ZTF) alert stream from December 2019 (as ZTF19acnskyy). This variability behaviour, coupled with the host-galaxy properties, suggests that SDSS1335+0728 hosts a ∼ 106M⊙ black hole (BH) that is currently in the process of ‘turning on’. Aims. We present a multi-wavelength photometric analysis and spectroscopic follow-up performed with the aim of better understanding the origin of the nuclear variations detected in SDSS1335+0728. Methods. We used archival photometry (from WISE, 2MASS, SDSS, GALEX, eROSITA) and spectroscopic data (from SDSS and LAMOST) to study the state of SDSS1335+0728 prior to December 2019, and new observations from Swift, SOAR/Goodman, VLT/X-shooter, and Keck/LRIS taken after its turn-on to characterise its current state. We analysed the variability of SDSS1335+0728 in the X-ray/UV/optical/mid-infrared range, modelled its spectral energy distribution prior to and after December 2019, and studied the evolution of its UV/optical spectra. Results. From our multi-wavelength photometric analysis, we find that: (a) since 2021, the UV flux (from Swift/UVOT observations) is four times brighter than the flux reported by GALEX in 2004; (b) since June 2022, the mid-infrared flux has risen more than two times, and the W1−W2 WISE colour has become redder; and (c) since February 2024, the source has begun showing X-ray emission. From our spectroscopic follow-up, we see that (i) the narrow emission line ratios are now consistent with a more energetic ionising continuum; (ii) broad emission lines are not detected; and (iii) the [OIII] line increased its flux ∼ 3.6 years after the first ZTF alert, which implies a relatively compact narrow-line-emitting region. Conclusions. We conclude that the variations observed in SDSS1335+0728 could be either explained by a ∼ 106M⊙ AGN that is just turning on or by an exotic tidal disruption event (TDE). If the former is true, SDSS1335+0728 is one of the strongest cases of an AGNobserved in the process of activating. If the latter were found to be the case, it would correspond to the longest and faintest TDE ever observed (or another class of still unknown nuclear transient). Future observations of SDSS1335+0728 are crucial to further understand its behaviour. Key words. galaxies: active– accretion, accretion discs– galaxies: individual: SDSS J133519.91+072807.4
Embracing Deep Variability For Reproducibility and Replicability
Abstract: Reproducibility (aka determinism in some cases) constitutes a fundamental aspect in various fields of computer science, such as floating-point computations in numerical analysis and simulation, concurrency models in parallelism, reproducible builds for third parties integration and packaging, and containerization for execution environments. These concepts, while pervasive across diverse concerns, often exhibit intricate inter-dependencies, making it challenging to achieve a comprehensive understanding. In this short and vision paper we delve into the application of software engineering techniques, specifically variability management, to systematically identify and explicit points of variability that may give rise to reproducibility issues (eg language, libraries, compiler, virtual machine, OS, environment variables, etc). The primary objectives are: i) gaining insights into the variability layers and their possible interactions, ii) capturing and documenting configurations for the sake of reproducibility, and iii) exploring diverse configurations to replicate, and hence validate and ensure the robustness of results. By adopting these methodologies, we aim to address the complexities associated with reproducibility and replicability in modern software systems and environments, facilitating a more comprehensive and nuanced perspective on these critical aspects.
https://hal.science/hal-04582287
4. ILEO-CECAL DYSBIOSIS IN CHRONIC LIVER DISEASE
Guarner C & Runyon BA. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J
Hepatol 1997
Pardo A, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis.
Hepatology 2000
Francés R, et al. Bacterial translocation is downregulated by anti-TNF-alpha monoclonal antibody administration
in rats with cirrhosis and ascites. J Hepatol 2007
5. SERUM MICROBIOME IN CHRONIC LIVER DISEASE
Santiago et al. Scientific Reports 2016
7. Decision making in the adaptive (acquired) immune system is
instructed by the microbial impact on APCs and T cells
CD4
TCR
APC
CD4
Th1, Th17
Treg
Foxp3+
Th2
TNF-, IFN- IL-17
IL-10
IL-4, IL-5, IL-13
CD4
CD4
+
–
–
–
–
PRR
Foreign antigen
(Ag)
Naive T-cell
activation
Cytokines
+
TGF-b
Signatures via pattern
recognition receptors
(PRRs): TLRs & NLRs
(NOD+LRR)
Ligation
MHC II
T
+
By Per Brandtzaeg in Guarner et al, Nature Clin Practice 2006
8. F
F
FAE
Gut-Associated Lymphoid Tissue structures are strategically situated in relation to the
greatest concentration of microbiota
• Peyer’s patches:
distal ileum (nos. 100-250)
• Isolated lymphoid follicles (ILFs):
large bowel (nos. ~ 30 000)
Brandtzaeg, Immunological Investigations 2010
9. HUMAN BLOOD REGULATORY CELLS INDUCED BY
Faecalibacterium prausnitzii
Sarrabayrouse et al, PLoS Biol 2014
13. THE ENEMY IS WITHIN THE FAECAL STREAM
Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R,
Vantrappen G.
Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal
ileum. Lancet 1991;338:771-4.
Winslet MC, Allan A, Poxon V, Youngs D, Keighley MR.
Faecal diversion for Crohn's colitis: a model to study the role of the faecal stream in the
inflammatory process. Gut 1994;35:236-42.
D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P.
Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in
excluded ileum. Gastroenterology 1998;114:262–267.
15. Adapted from Holtmann et al. Z Gastroenterol 2002
Cell detachment
Macrophage
TNF-
TNF-
Severe tissue injury by inflammation: role of TNF-
enderetal,JImmunol1998
16. Modern life style Traditional lifestye
Birth in the hospital; increasing rate of caesarean delivery Vaginal delivery at home
Small family size Large family size, crowding
Life on concrete Life in contact with soil microorganisms
Sanitation of living spaces: environment colonized by
resistant micro-organisms (including resistant bacteria,
fungii, acari)
Ancestral colonization of the living environment
Antibiotic usage early in life No antibiotics in infant life
Daily body wash with hot water and soap Limited access to hot water and soap
Low rate of H. pylori colonization High rate of H. pylori colonization
Decline in endemic parasitism Common carriage of parasitic worms
Food conserved by refrigeration Food conserved by microbial fermentation
Consumption of processed foods Consumption of natural foods
IBD risk factors are linked with altered microbial colonization
Manichanh et al, Nature Reviews Gastroenterology 2012
23. Gene Richness and Species Diversity
Nielsen et al, Nature Biotechnology 2014
24. • Richness is greatly altered in Crohn’s
Disease
•* • *
•Gene Count •Species count
•Genes,N°
•MGS,N°
•050000010000001500000
•0100200300400
500
•p = 4.3e-10 (wilcox. test) • p = 4.9e-9 (wilcox. test)
•Healthy, n = 52 •CD, n = 73 •Healthy, n = 52 •CD, n = 73
•24
25. Richness is less altered in Ulcerative Colitis
*
MGS,N°
Genes,N°
p = 0.15 (wilcox. test)
Gene Count Species count
p = 0.019 (wilcox. test)
Healthy, n = 56 Healthy, n = 56UC, n = 65 UC, n = 65
2000006000001000000
100200300400500
•25Maziers et al, IHMC 2016
26. •26
Strong Species signal in CD Healthy, n = 52 CD, n = 73
Healthy
CD
Richness
Numerous Faecalibacterium spp
Maziers et al, IHMC 2016
27. Less strong Species signal associated with UC Healthy, n = 28 HR, n = 28 UC -1, n = 34 UC-2, n = 31
Healthy
UC
Richness •27
Maziers et al, IHMC 2016
28. • Reduction of SCFA producing bacteria (butyrate producers such as
Faecalibacterium, Roseburia, Lachnospiraceae, Eubacterium, Subdoligranulum).
• Increased mucus degradation potential by abnormal mucin degraders that
displace Akkermansia.
• Reduced hydrogen and methane production potential combined with increased
hydrogen sulphide formation potential. Hydrogen sulphide is toxic for the
epithelium.
• Increase in abundance of bacteria with LPS endotoxins (Proteobacteria) that
can drive inflammation.
• Increased potential to manage oxidative stress, i.e. microbes become able to
proliferate in close vicinity to the epithelium.
29. Conclusiones
• En pacientes con EII, hay una distorsión permanente del ecosistema microbiano
intestinal, incluso durante períodos de remisión, caracterizada por reducción de
riqueza de genes microbianos, reducción de la diversidad de especies e
inestabilidad de la comunidad.
• CD y UC tienen firmas microbianas distintas a nivel taxonómico, pero las
alteraciones funcionales son parecidas.
• Los cambios son más intensos en pacientes con CD, mientras que los pacientes
UC presentan mejor recuperación durante los períodos de remisión.
30. Acknowledgments
MetaHIT
Consortium
HUVH: V. Robles, N. Borruel, F. Casellas,
F. Guarner
INRA: E. Le Chatelier, N. Maziers, D.
Ehrlich
La Fe (Valencia) : B. Beltrán, P. Nos
Parc Tauli (Sabadell) : A. Villoria, X. Calvet